

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * SCO CAPITAL PARTNERS LLC		2. Issuer Name and Ticker or Trading Symbol ACCESS PHARMACEUTICALS INC [ACCP.OB]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ <input checked="" type="checkbox"/> 10% Owner Officer (give title below) _____ Other (specify below) _____	
(Last) 1285 AVENUE OF THE AMERICAS, 35TH FLOOR	(First) NEW YORK, NY 10019	(Middle) NEW YORK, NY 10019	3. Date of Earliest Transaction (Month/Day/Year) 01/04/2008		6. Individual or Joint/Group Filing (Check Applicable Line) ____ Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person
(Street)	(City)	(State)	(Zip)	4. If Amendment, Date Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/04/2008		J(1)		787,796	A	(1)	787,796	D (2) (3)	
Common Stock	01/04/2008		J(4)		11,447	A	(4)	11,447	I	By The Steven H. Rouhandeh 1999 Family Trust (5)
Common Stock	01/04/2008		J(4)		11,447	A	(4)	11,447	I	By The Chloe H. Rouhandeh Trust (5)
Common Stock	01/04/2008		J(4)		11,447	A	(4)	11,447	I	By The Sophie C. Rouhandeh Trust (5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)



1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date					
Common Stock Purchase Warrant	\$ 23.19	01/04/2008		J(6)	88,574		01/04/2008	01/31/2012	Common Stock	88,574	(6)	88,574	D (2) (3)
Common Stock Purchase Warrant	\$ 18.55	01/04/2008		J(7)	19,170		01/04/2008	01/31/2012	Common Stock	19,170	(7)	19,170	D (2) (3)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SCO CAPITAL PARTNERS LLC 1285 AVENUE OF THE AMERICAS 35TH FLOOR		X		

NEW YORK, NY 10019				
Rouhandeh Steven H C/O SCO CAPITAL PARTNERS LLC 1285 AVENUE OF THE AMERICAS, 35TH FLOOR NEW YORK, NY 10019		X		

Signatures

SCO Capital Partners LLC		01/08/2008
		Date
Steven H. Rouhandeh		01/08/2008
		Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- Received in exchange for 7,183,259 shares of Somanta Pharmaceuticals, Inc. common stock and 328,6318 shares of Somanta Pharmaceuticals, Inc. Series A Convertible Preferred Stock in connection with the merger of Somanta Pharmaceuticals, Inc. into Access Pharmaceuticals, Inc. (the "Merger"). Pursuant to the Merger, each share of Somanta Pharmaceuticals, Inc. common stock was converted into 0.03234333 shares of Access Pharmaceuticals, Inc. common stock and each share of Somanta Pharmaceuticals, Inc. Series A Convertible Preferred Stock was converted into 1,690.24045022 shares of Access Pharmaceuticals, Inc. common stock. On the effective date of the Merger, the closing price of Somanta Pharmaceuticals, Inc. common stock was \$0.12 per share, and the closing price of Access Pharmaceuticals, Inc. common stock was \$3.10 per share.
- (1) Pharmaceuticals, Inc. common stock was converted into 0.03234333 shares of Access Pharmaceuticals, Inc. common stock and each share of Somanta Pharmaceuticals, Inc. Series A Convertible Preferred Stock was converted into 1,690.24045022 shares of Access Pharmaceuticals, Inc. common stock. On the effective date of the Merger, the closing price of Somanta Pharmaceuticals, Inc. common stock was \$0.12 per share, and the closing price of Access Pharmaceuticals, Inc. common stock was \$3.10 per share.
- (2) This Form 4 is being filed by Steven H. Rouhandeh individually and by SCO Capital Partners LLC, an entity of which Mr. Rouhandeh is the managing member.
- (3) SCO Capital Partners LLC is the direct beneficial owner of these securities.
- Received in exchange for 353,925 shares of Somanta Pharmaceuticals, Inc. common stock in connection with the Merger of Somanta Pharmaceuticals, Inc. into Access Pharmaceuticals, Inc.. On the effective date of the Merger, the closing price of Somanta Pharmaceuticals, Inc. common stock was \$0.12 per share, and the closing price of Access Pharmaceuticals, Inc. common stock was \$3.10 per share.
- (4) Pharmaceuticals, Inc.. On the effective date of the Merger, the closing price of Somanta Pharmaceuticals, Inc. common stock was \$0.12 per share, and the closing price of Access Pharmaceuticals, Inc. common stock was \$3.10 per share.
- (5) Steven H. Rouhandeh is one of the trustees of this entity.
- (6) Received in the Merger in exchange for warrants to purchase 2,738,598 shares of Somanta Pharmaceuticals, Inc. common stock at an exercise price of \$0.75 per share.
- (7) Received in the Merger in exchange for warrants to purchase 592,732 shares of Somanta Pharmaceuticals, Inc. common stock at an exercise price of \$0.60 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.